Wouter C Meijers1, Manuel Maglione2, Stephan J L Bakker3, Rupert Oberhuber2, Lyanne M Kieneker3, Steven de Jong4, Bernhard J Haubner5, Wouter B Nagengast6, Alexander R Lyon7, Bert van der Vegt8, Dirk J van Veldhuisen1, B Daan Westenbrink1, Peter van der Meer1, Herman H W Silljé1, Rudolf A de Boer1. 1. Department of Cardiology (W.C.M., D.J.v.V., B.D.W., P.v.d.M., H.H.W.S., R.A.d.B.). 2. Centre of Operative Medicine, Department of Visceral, Transplant and Thoracic Surgery (M.M., R.O.). 3. Department of Internal Medicine, Division of Nephrology (S.J.L.B., L.M.K.), University Medical Center Groningen, University of Groningen, The Netherlands. 4. Department of Medical Oncology (S.d.J.). 5. Department of Internal Medicine III (Cardiology and Angiology) (B.J.H.), Medical University of Innsbruck, Austria. 6. Department of Gastroenterology and Hepatology (W.B.N.). 7. National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, United Kingdom (A.R.L.). 8. Department of Pathology (B.v.d.V.).
Abstract
BACKGROUND: Heart failure (HF) survival has improved, and nowadays, many patients with HF die of noncardiac causes, including cancer. Our aim was to investigate whether a causal relationship exists between HF and the development of cancer. METHODS: HF was induced by inflicting large anterior myocardial infarction in APCmin mice, which are prone to developing precancerous intestinal tumors, and tumor growth was measured. In addition, to rule out hemodynamic impairment, a heterotopic heart transplantation model was used in which an infarcted or sham-operated heart was transplanted into a recipient mouse while the native heart was left in situ. After 6 weeks, tumor number, volume, and proliferation were quantified. Candidate secreted proteins were selected because they were previously associated both with (colon) tumor growth and with myocardial production in post-myocardial infarction proteomic studies. Myocardial gene expression levels of these selected candidates were analyzed, as well as their proliferative effects on HT-29 (colon cancer) cells. We validated these candidates by measuring them in plasma of healthy subjects and patients with HF. Finally, we associated the relation between cardiac specific and inflammatory biomarkers and new-onset cancer in a large, prospective general population cohort. RESULTS: The presence of failing hearts, both native and heterotopically transplanted, resulted in significantly increased intestinal tumor load of 2.4-fold in APCmin mice (all P<0.0001). The severity of left ventricular dysfunction and fibrotic scar strongly correlated with tumor growth ( P=0.002 and P=0.016, respectively). We identified several proteins (including serpinA3 and A1, fibronectin, ceruloplasmin, and paraoxonase 1) that were elevated in human patients with chronic HF (n=101) compared with healthy subjects (n=180; P<0.001). Functionally, serpinA3 resulted in marked proliferation effects in human colon cancer (HT-29) cells, associated with Akt-S6 phosphorylation. Finally, elevated cardiac and inflammation biomarkers in apparently healthy humans (n=8319) were predictive of new-onset cancer (n=1124) independently of risk factors for cancer (age, smoking status, and body mass index). CONCLUSIONS: We demonstrate that the presence of HF is associated with enhanced tumor growth and that this is independent of hemodynamic impairment and could be caused by cardiac excreted factors. A diagnosis of HF may therefore be considered a risk factor for incident cancer.
BACKGROUND:Heart failure (HF) survival has improved, and nowadays, many patients with HF die of noncardiac causes, including cancer. Our aim was to investigate whether a causal relationship exists between HF and the development of cancer. METHODS: HF was induced by inflicting large anterior myocardial infarction in APCmin mice, which are prone to developing precancerous intestinal tumors, and tumor growth was measured. In addition, to rule out hemodynamic impairment, a heterotopic heart transplantation model was used in which an infarcted or sham-operated heart was transplanted into a recipient mouse while the native heart was left in situ. After 6 weeks, tumor number, volume, and proliferation were quantified. Candidate secreted proteins were selected because they were previously associated both with (colon) tumor growth and with myocardial production in post-myocardial infarction proteomic studies. Myocardial gene expression levels of these selected candidates were analyzed, as well as their proliferative effects on HT-29 (colon cancer) cells. We validated these candidates by measuring them in plasma of healthy subjects and patients with HF. Finally, we associated the relation between cardiac specific and inflammatory biomarkers and new-onset cancer in a large, prospective general population cohort. RESULTS: The presence of failing hearts, both native and heterotopically transplanted, resulted in significantly increased intestinal tumor load of 2.4-fold in APCmin mice (all P<0.0001). The severity of left ventricular dysfunction and fibrotic scar strongly correlated with tumor growth ( P=0.002 and P=0.016, respectively). We identified several proteins (including serpinA3 and A1, fibronectin, ceruloplasmin, and paraoxonase 1) that were elevated in humanpatients with chronic HF (n=101) compared with healthy subjects (n=180; P<0.001). Functionally, serpinA3 resulted in marked proliferation effects in humancolon cancer (HT-29) cells, associated with Akt-S6 phosphorylation. Finally, elevated cardiac and inflammation biomarkers in apparently healthy humans (n=8319) were predictive of new-onset cancer (n=1124) independently of risk factors for cancer (age, smoking status, and body mass index). CONCLUSIONS: We demonstrate that the presence of HF is associated with enhanced tumor growth and that this is independent of hemodynamic impairment and could be caused by cardiac excreted factors. A diagnosis of HF may therefore be considered a risk factor for incident cancer.
Authors: Manol Jovani; Elizabeth E Liu; Samantha M Paniagua; Emily S Lau; Shawn X Li; Katherine S Takvorian; Bernard E Kreger; Greta Lee Splansky; Rudolf A de Boer; Amit D Joshi; Shih Jen Hwang; Chen Yao; Tianxiao Huan; Paul Courchesne; Martin G Larson; Daniel Levy; Andrew T Chan; Jennifer E Ho Journal: Cardiovasc Res Date: 2022-07-27 Impact factor: 13.081
Authors: Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky Journal: J Am Coll Cardiol Date: 2020-06-02 Impact factor: 24.094
Authors: Graeme J Koelwyn; Joseph Pierre Aboumsallem; Kathryn J Moore; Rudolf A de Boer Journal: J Mol Cell Cardiol Date: 2021-09-25 Impact factor: 5.000
Authors: Texali C Garcia-Garduño; Jorge R Padilla-Gutierrez; Diego Cambrón-Mora; Yeminia Valle Journal: Int J Mol Sci Date: 2021-07-01 Impact factor: 5.923
Authors: Rudolf A de Boer; Joseph Pierre Aboumsallem; Valentina Bracun; Douglas Leedy; Richard Cheng; Sahishnu Patel; David Rayan; Svetlana Zaharova; Jennifer Rymer; Jennifer M Kwan; Joshua Levenson; Claudio Ronco; Paaladinesh Thavendiranathan; Sherry-Ann Brown Journal: Cardiooncology Date: 2021-06-21